US Patent

US7417070 — Compounds and methods for delivery of prostacyclin analogs

Composition of Matter · Assigned to United Therapeutics Corp · Expires 2026-07-30 · 0y remaining

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds and methods that increase the oral bioavailability and circulating concentrations of treprostinil diolamine.

USPTO Abstract

This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula:

Drugs covered by this patent

Patent Metadata

Patent number
US7417070
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-07-30
Drug substance claim
Yes
Drug product claim
No
Assignee
United Therapeutics Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.